Recent research have centered on the overlap of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopaminergic communication. While GIP agonists are widely employed for treating type 2 diabetes mellitus, their emerging consequences on r